Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | Director | March 06, 2023 | March 09, 2023 |
| Alpha Teknova, Inc.TKNO · Entity 5715 | Director | July 14, 2026 | July 16, 2026 |
| Equillium, Inc.EQ · Entity 6560 | Director | May 28, 2026 | May 29, 2026 |
| Evofem Biosciences, Inc.NEOT · Entity 8607 | Director | June 20, 2017 | June 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date March 06, 2023 · Filed March 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 56,601 |
Reported balance
After 2023-03-06 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-03-06 · Grant · Acquired 25,815 · Balance 56,601 F1: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2: Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 13,293 RSUs granted on March 7, 2022, which will vest in full on March 7, 2023; and (iii) 17,493 shares of common stock owned by the reporting person. F3: These shares are held in the trust account of the Martha J. Demski Trust U/D/T 10/01/94, for which the reporting person serves as trustee. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2033-03-06 | Direct | 51,630 |
Reported balance
After 2023-03-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-06 · Grant · Acquired 51,630 · Balance 51,630 F4: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.
F2: Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 13,293 RSUs granted on March 7, 2022, which will vest in full on March 7, 2023; and (iii) 17,493 shares of common stock owned by the reporting person.
F3: These shares are held in the trust account of the Martha J. Demski Trust U/D/T 10/01/94, for which the reporting person serves as trustee.
F4: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.
Alpha Teknova, Inc.
Report date July 14, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-14 transaction · row 1
1 source rowRow 1 · 2026-07-14 · Other · Disposed 12,000 · Balance 0 F1: This transaction reflects the transfer of 12,000 shares of Common Stock from the Reporting Person's individual account to a trust for which the Reporting Person serves as trustee. No sale or other change in beneficial ownership occurred as a result of this transfer. F2: No consideration was paid or received in connection with this transaction, as it represents a personal transfer of shares between accounts controlled by the Reporting Person, and not an open-market or arms'-length transaction. Accordingly, no price is reported. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 12,000 |
Reported balance
After 2026-07-14 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-14 · Other · Acquired 12,000 · Balance 12,000 F1: This transaction reflects the transfer of 12,000 shares of Common Stock from the Reporting Person's individual account to a trust for which the Reporting Person serves as trustee. No sale or other change in beneficial ownership occurred as a result of this transfer. F2: No consideration was paid or received in connection with this transaction, as it represents a personal transfer of shares between accounts controlled by the Reporting Person, and not an open-market or arms'-length transaction. Accordingly, no price is reported. F3: The Reporting Person is the trustee of the trust and retains sole voting and investment power over the shares held therein. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if applicable. F4: Represents the total number of shares of Common Stock held by the trust following the reported transaction. This is the first transaction reporting shares beneficially owned indirectly through this trust. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction reflects the transfer of 12,000 shares of Common Stock from the Reporting Person's individual account to a trust for which the Reporting Person serves as trustee. No sale or other change in beneficial ownership occurred as a result of this transfer.
F2: No consideration was paid or received in connection with this transaction, as it represents a personal transfer of shares between accounts controlled by the Reporting Person, and not an open-market or arms'-length transaction. Accordingly, no price is reported.
F3: The Reporting Person is the trustee of the trust and retains sole voting and investment power over the shares held therein. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if applicable.
F4: Represents the total number of shares of Common Stock held by the trust following the reported transaction. This is the first transaction reporting shares beneficially owned indirectly through this trust.
Equillium, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2036-05-27 | Direct | 70,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 70,000 · Balance 70,000 F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
Evofem Biosciences, Inc.
Report date June 20, 2017 · Filed June 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2027-06-20 | Direct | 12,450 |
Reported balance
After 2017-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-20 · Grant · Acquired 12,450 · Balance 12,450 F1: Option shares fully vest on the earlier of (i) June 20, 2018, (ii) the day preceding the Issuer's annual meeting of stockholders held in 2018, or (iii) immediately prior to a change of control as contemplated by the Issuer's 2014 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Option shares fully vest on the earlier of (i) June 20, 2018, (ii) the day preceding the Issuer's annual meeting of stockholders held in 2018, or (iii) immediately prior to a change of control as contemplated by the Issuer's 2014 Equity Incentive Plan.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Adamas Pharmaceuticals Inc
Report date November 24, 2021 · Filed November 24, 2021
Section 16 reporting ended · disclosed 2021-11-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectMartha J. Demski U/D/T 10/1/1994, Martha J. Demski Trustee | 0 |
Reported balance
After 2021-11-24 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-11-24 · Other · Disposed 16,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F2: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 2
1 source rowRow 2 · 2021-11-24 · Other · Disposed 5,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F3: Amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price. F2: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2029-06-04 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-24 · Disposition to issuer · Disposed 10,000 · Balance 0 F6: $3.30 plus two CVRs per share underlying the stock option. F4: The stock option is fully vested and exercisable. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2030-06-02 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-24 · Disposition to issuer · Disposed 10,000 · Balance 0 F7: $5.40 plus two CVRs per share underlying the stock option. F4: The stock option is fully vested and exercisable. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-24 · Disposition to issuer · Disposed 10,000 · Balance 0 F8: $2.89 plus two CVRs per share underlying the stock option. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price").
F2: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value.
F3: Amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price.
F4: The stock option is fully vested and exercisable.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.
F6: $3.30 plus two CVRs per share underlying the stock option.
F7: $5.40 plus two CVRs per share underlying the stock option.
F8: $2.89 plus two CVRs per share underlying the stock option.
CHIMERIX INC
Report date April 21, 2025 · Filed April 21, 2025
Section 16 reporting ended · disclosed 2025-04-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Martha J. Demski Trust u/a 10/01/94 | 0 |
Reported balance
After 2025-04-21 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-04-21 · Disposition to issuer · Disposed 72,055 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.73 · Expires 2026-06-23 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-21 · Disposition to issuer · Disposed 9,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.15 · Expires 2025-06-21 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-21 · Disposition to issuer · Disposed 9,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Shares other than an In the Money Option that is then outstanding and unexercised, whether or not vested, was cancelled at the Effective Time with no consideration payable in respect thereof. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2027-06-27 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-04-21 · Disposition to issuer · Disposed 21,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.82 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-04-21 · Disposition to issuer · Disposed 21,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2029-06-19 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-04-21 · Disposition to issuer · Disposed 21,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.85 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-04-21 · Disposition to issuer · Disposed 35,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.84 · Expires 2031-06-22 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-04-21 · Disposition to issuer · Disposed 35,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.82 · Expires 2032-06-22 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-04-21 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-04-21 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2034-06-19 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-04-21 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]
F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.
F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).
F4: Pursuant to the Merger Agreement, each option to purchase Shares other than an In the Money Option that is then outstanding and unexercised, whether or not vested, was cancelled at the Effective Time with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2021 Filed May 28, 2021 22:10 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 20,770 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-036635 · doc4.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,770 Underlying: Common Stock · 20,770 shares Expires 2031-05-26 F1 · derivative.exercise_date: These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided that the options will, in any case, be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2018 Equity Incentive Plan (the "Plan")), through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:04 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001193805-21-000298 · e620333_4-demski.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: The options vest in twelve equal monthly installments, becoming fully vested on February 25, 2022. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 12:57 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,042 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-20-059336 · doc4.xml · derivative · entry 4 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,042 shares Expires 2021-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 12:57 UTC | CHIMERIX INC CMRX · Entity 80651 | GiftCommon Stock | 7,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059336 · doc4.xml · nonDerivative · entry 3 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Martha J. Demski Trust u/a 10/01/94 Disclosed balance after: 44,055 F1 · kind: This transaction involved a gift of securities by the reporting person to the Martha J. Demski Trust u/a 10/01/94. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 12:57 UTC | CHIMERIX INC CMRX · Entity 80651 | GiftCommon Stock | 7,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059336 · doc4.xml · nonDerivative · entry 2 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction involved a gift of securities by the reporting person to the Martha J. Demski Trust u/a 10/01/94. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 12:57 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionCommon Stock | 7,042 | $2.35 | $16,548.70 |
DisclosureSEC source: 0001209191-20-059336 · doc4.xml · nonDerivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 12:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 2,200 | $2.29 | $5,038.00 |
DisclosureSEC source: 0001193805-20-001139 · e619929_4-demski.xml · nonDerivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,200 F1 · ownership.nature: These shares are held in the trust account of the Martha J. Demski Trust U/D/T 10/01/94, for which the reporting person serves as trustee. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 12:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 2,000 | $2.88 | $5,760.00 |
DisclosureSEC source: 0001193805-20-001036 · e619873_4-demski.xml · nonDerivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,000 F1 · ownership.nature: These shares are held in the trust account of the Martha J. Demski Trust U/D/T 10/01/94, for which the reporting person serves as trustee. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 17:49 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,584 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001209191-20-046206 · doc4.xml · derivative · entry 4 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,584 shares Expires 2020-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 17:49 UTC | CHIMERIX INC CMRX · Entity 80651 | SaleCommon Stock | 1,584 | $3.25 | $5,148.48 |
DisclosureSEC source: 0001209191-20-046206 · doc4.xml · nonDerivative · entry 2 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on March 10, 2020. F2 · price: The range of sale prices received is $3.25 to $3.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares sold at each separate price. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 17:49 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionCommon Stock | 1,584 | $3.16 | $5,005.44 |
DisclosureSEC source: 0001209191-20-046206 · doc4.xml · nonDerivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 17:54 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001209191-20-045996 · doc4.xml · derivative · entry 7 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,584 Underlying: Common Stock · 2,500 shares Expires 2020-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 17:54 UTC | CHIMERIX INC CMRX · Entity 80651 | SaleCommon Stock | 2,500 | $3.25 | $8,125.00 |
DisclosureSEC source: 0001209191-20-045996 · doc4.xml · nonDerivative · entry 4 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on March 10, 2020. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 17:54 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionCommon Stock | 2,500 | $3.16 | $7,900.00 |
DisclosureSEC source: 0001209191-20-045996 · doc4.xml · nonDerivative · entry 3 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 17:54 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001209191-20-045996 · doc4.xml · derivative · entry 6 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,084 Underlying: Common Stock · 2,500 shares Expires 2020-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 17:54 UTC | CHIMERIX INC CMRX · Entity 80651 | SaleCommon Stock | 2,500 | $3.29 | $8,223.75 |
DisclosureSEC source: 0001209191-20-045996 · doc4.xml · nonDerivative · entry 2 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on March 10, 2020. F2 · price: The range of sale prices received is $3.26 to $3.44. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares sold at each separate price. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 17:54 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionCommon Stock | 2,500 | $3.16 | $7,900.00 |
DisclosureSEC source: 0001209191-20-045996 · doc4.xml · nonDerivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 12:55 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001209191-20-045424 · doc4.xml · derivative · entry 7 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,584 Underlying: Common Stock · 2,500 shares Expires 2020-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 12:55 UTC | CHIMERIX INC CMRX · Entity 80651 | SaleCommon Stock | 2,500 | $3.27 | $8,187.25 |
DisclosureSEC source: 0001209191-20-045424 · doc4.xml · nonDerivative · entry 4 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on March 10, 2020. F2 · price: The range of sale prices received is $3.25 to $3.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 12:55 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionCommon Stock | 2,500 | $3.16 | $7,900.00 |
DisclosureSEC source: 0001209191-20-045424 · doc4.xml · nonDerivative · entry 3 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2020 Filed Aug 6, 2020 12:55 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001209191-20-045424 · doc4.xml · derivative · entry 6 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,084 Underlying: Common Stock · 5,000 shares Expires 2020-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 04, 2020 Filed Aug 6, 2020 12:55 UTC | CHIMERIX INC CMRX · Entity 80651 | SaleCommon Stock | 5,000 | $3.25 | $16,250.00 |
DisclosureSEC source: 0001209191-20-045424 · doc4.xml · nonDerivative · entry 2 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on March 10, 2020. Read SEC document |
| August 04, 2020 Filed Aug 6, 2020 12:55 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionCommon Stock | 5,000 | $3.16 | $15,800.00 |
DisclosureSEC source: 0001209191-20-045424 · doc4.xml · nonDerivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2020 Filed Jun 18, 2020 22:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001193805-20-000713 · e619706_4-demski.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: Reflects the grant of a stock option to purchase 30,000 shares of common stock, $0.0001 par value per share ("Common Stock") of ADMA Biologics, Inc. The shares of Common Stock underlying the stock option will vest in 12 equal monthly installments, becoming fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service on the applicable vesting date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 12:37 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001209191-20-036521 · doc4.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 22:07 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-20-034776 · doc4.xml · derivative · entry 3 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-02 F2 · derivative.exercise_date: The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from June 3, 2020, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 22:07 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034776 · doc4.xml · nonDerivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the date 1 year from June 3, 2020, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:30 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001209191-20-031273 · doc4.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-05-19 F1 · derivative.exercise_date: The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 14:33 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001209191-19-038722 · doc4.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:35 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0001209191-19-036798 · doc4.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:12 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-19-035051 · doc4.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-04 F1 · derivative.exercise_date: The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from June 5, 2019, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| May 28, 2019 Filed May 29, 2019 12:29 UTC | CHIMERIX INC CMRX · Entity 80651 | PurchaseCommon Stock | 18,000 | $3.60 | $64,800.00 |
DisclosureSEC source: 0001209191-19-033140 · doc4.xml · nonDerivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Martha J. Demski Trust u/a 10/01/94 Disclosed balance after: 37,013 Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 17:42 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001209191-18-039005 · doc4.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2019 annual stockholder meeting. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 21:00 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $27.98 | $0.00 |
DisclosureSEC source: 0001209191-18-036405 · doc4.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from June 6, 2018, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| May 09, 2018 Filed May 10, 2018 15:20 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,225 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001209191-18-029206 · doc4.xml · derivative · entry 2 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,225 shares Expires 2019-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares vest in 48 equal monthly installments commencing on June 5, 2009. Read SEC document |
| May 09, 2018 Filed May 10, 2018 15:20 UTC | CHIMERIX INC CMRX · Entity 80651 | Exercise / conversionCommon Stock | 4,225 | $1.57 | $6,633.25 |
DisclosureSEC source: 0001209191-18-029206 · doc4.xml · nonDerivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Martha J. Demski Trust u/a 10/01/94 Disclosed balance after: 19,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2017 Filed Jun 29, 2017 16:21 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $5.53 | $0.00 |
DisclosureSEC source: 0001209191-17-042290 · doc4.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2018 annual stockholder meeting. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 01:40 UTC | Evofem Biosciences, Inc. NEOT · Entity 8607 | GrantStock Option (Right to Buy) · Derivative | 12,450 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-17-041270 · doc4.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,450 Underlying: Common Stock · 12,450 shares Expires 2027-06-20 F1 · derivative.exercise_date: Option shares fully vest on the earlier of (i) June 20, 2018, (ii) the day preceding the Issuer's annual meeting of stockholders held in 2018, or (iii) immediately prior to a change of control as contemplated by the Issuer's 2014 Equity Incentive Plan. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 20:41 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $16.27 | $0.00 |
DisclosureSEC source: 0001209191-17-037311 · doc4.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from June 1, 2017, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| May 11, 2017 Filed May 12, 2017 00:42 UTC | Evofem Biosciences, Inc. NEOT · Entity 8607 | GrantStock Option (Right to Buy) · Derivative | 63,500 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001209191-17-031690 · doc4.xml · derivative · entry 1 DEMSKI MARTHA J · CIK 0001198230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,500 Underlying: Common Stock · 63,500 shares Expires 2027-05-11 F1 · derivative.exercise_date: Option shares vest and become exercisable in twelve (12) equal monthly installments measured from the vesting commencement date, February 15, 2017, with full acceleration of the option shares upon the event of a change in control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.